Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2026 financial results after market close on Thursday, November 5, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
Rigel Pharmaceuticals Shares Rose Even As Profit Fell
If you only saw Rigel Pharmaceuticals’ latest quarterly results, with revenue and net income both lower than a year earlier and net margin compressed from 58.6% to 22.0%, you might assume shareholders had a rough ride. Investors who held Rigel Pharmaceuticals over the past year are up 66.2%, including dividends. If you were weighing an investment on 22 October 2025, what did the mix of pipeline promise and earnings quality really signal about taking that risk? Rigel Pharmaceuticals is not the...
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced analysis of the pooled efficacy and safety data from two clinical trials of GAVRETO® (pralsetinib), ARROW (NCT03037385) and TAPISTRY (NCT04589845), in patients with rearranged during transfection (RET) fusion-positive solid tumors will be presented in a rapid oral session at the European Society For Medical Oncology (ESMO) Congress 2026 on Sunday, Octo
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $85 price target.
Reasons Why Investors Should Consider Betting on Arvinas Stock
ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.
Knight Therapeutics Announces Launch of TAVALISSE® in Brazil
MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1 “With today's launch, TAVALISSE® is now available to adults in Brazil living with chronic ITP who have not responded adequately to
Based on $RIGL's market cap and volume profile, our model suggests a systematic entry approach:
This scaling approach reduces timing risk and provides multiple entry points for volatility management.
⚠️ This is not investing or trading advice. This is just an AI generated model and suggestion tool. Not advice ever.
| DATE | OPEN | HIGH | LOW | CLOSE | CHANGE | CHANGE % |
|---|---|---|---|---|---|---|
| Invalid Date | $51.33 | $51.84 | $50.00 | $50.53 | $-0.80 | -1.56% |
| Invalid Date | $51.80 | $52.60 | $50.67 | $51.31 | $-0.49 | -0.95% |
| Invalid Date | $51.17 | $51.60 | $50.24 | $51.45 | +$0.28 | +0.55% |
| Invalid Date | $50.26 | $51.36 | $50.05 | $50.74 | +$0.48 | +0.96% |
| Invalid Date | $50.09 | $50.70 | $49.54 | $50.55 | +$0.46 | +0.92% |
| Invalid Date | $48.63 | $50.00 | $48.32 | $49.91 | +$1.28 | +2.63% |
| Invalid Date | $48.48 | $48.48 | $47.47 | $48.13 | $-0.35 | -0.72% |
| Invalid Date | $48.97 | $49.94 | $48.55 | $48.86 | $-0.11 | -0.22% |
| Invalid Date | $47.64 | $49.01 | $47.64 | $48.88 | +$1.24 | +2.60% |
| Invalid Date | $46.73 | $48.16 | $46.73 | $48.11 | +$1.38 | +2.95% |
| Invalid Date | $46.39 | $47.38 | $45.48 | $46.72 | +$0.33 | +0.71% |
| Invalid Date | $47.58 | $47.58 | $45.68 | $45.97 | $-1.61 | -3.38% |
| Invalid Date | $47.01 | $48.52 | $47.01 | $47.25 | +$0.24 | +0.51% |
| Invalid Date | $46.82 | $47.99 | $46.37 | $46.82 | +$0.00 | +0.00% |
| Invalid Date | $48.70 | $48.87 | $47.04 | $47.14 | $-1.56 | -3.20% |
| Invalid Date | $49.22 | $49.89 | $48.53 | $48.81 | $-0.41 | -0.83% |
| Invalid Date | $48.60 | $50.49 | $48.60 | $49.08 | +$0.48 | +0.99% |
| Invalid Date | $47.33 | $48.89 | $46.56 | $48.72 | +$1.39 | +2.94% |
| Invalid Date | $45.64 | $48.15 | $45.22 | $47.99 | +$2.35 | +5.15% |
| Invalid Date | $48.18 | $48.18 | $45.93 | $46.11 | $-2.07 | -4.30% |
| Invalid Date | $47.02 | $48.83 | $46.93 | $47.79 | +$0.77 | +1.64% |